Author

Haruhiko Kamada

Kyoto UniversityORCID 0000-0002-2478-3818Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1

Frequent Co-Authors

Hiroaki OhnoiD· 2 shared Hiroki AkibaiD· 2 shared Satoshi NagataiD· 2 shared Tomoko IseiD· 2 shared Haruyo Konishi· 1 shared Junso FujitaiD· 1 shared Keiichi NambaiD· 1 shared Keita FukaoiD· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Hiroaki OhnoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistryJournal of Biological ChemistryPeer-reviewedJul 31, 2025

Conversion of an agonistic anti-TNFR2 biparatopic antibody into an antagonist by insertion of peptide linkers into the hinge region

Takuya Otsuki, Shigeyuki Matsumoto, Junso Fujita…·Hiroki Akiba

The paper converts an agonistic anti-TNFR2 biparatopic antibody into an antagonist by inserting peptide linkers into the hinge region, altering its immunocomplex formation.

2 citations

protein structureexperimental assay

𝕏 PostBluesky

BiochemistryAntibody TherapeuticsPeer-reviewedJan 1, 2025

Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule

Hiroki Akiba, Tomoko Ise, Reiko Satoh…·Satoshi Nagata

This study develops biparatopic anti-CD30 antibodies by determining epitopes and analyzing their agonistic and antagonistic activities.

3 citations

humanproteomics

𝕏 PostBluesky

MicrobiologyPLoS ONEPeer-reviewedDec 2, 2024

Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo

Yoji Tsugawa, Kentaro Furukawa, Tomoko Ise…·Satoshi Nagata

This study identifies an antibody, CV804, that targets the conserved S2 domain of coronaviruses and shows broad cross-reactivity and ADCC activity against SARS-CoV-2 and related viruses.

6 citations

humanproteomics

𝕏 PostBluesky